title: Enhancement of functional antibody responses to AMA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide.
abstract: Apical membrane antigen 1 (AMA1) has been shown to be a promising malaria vaccine candidate. The multiallelic AMA1-C1 vaccine currently in Phase 1 trials in the US and Mali contains an equal mixture of the ectodomain portion of recombinant AMA1 from the FVO and 3D7 clones of Plasmodium falciparum, formulated on Alhydrogel. It is hoped that inclusion of a human-optimized CpG oligodeoxynucleotide (ODN) (CPG 7909) with our existing AMA1-C1/Alhydrogel vaccine will lead to a higher concentration of functional AMA1-C1 antibodies. Preclinical studies were performed in mice, rats and guinea pigs to assess the safety, immunogenicity and functionality of the immune response to AMA1-C1 with Alhydrogel + CPG 7909 compared to antigen with Alhydrogel alone. Day 42 mean anti-AMA1 ELISA titer values derived from individual animals were compared between Alhydrogel and Alhydrogel + CPG 7909 groups at each antigen dose for each species. Sera from Alhydrogel + CPG 7909 groups displayed significantly higher antibody titers (P < 0.025) than their comparable Alhydrogel alone group. Mouse IgG isotype analysis showed that AMA1-C1/Alhydrogel induced a predominately Th2 type response while AMA1-C1/Alhydrogel + CPG 7909 gave a mixed Th1/Th2 type response. When tested for functional activity by in vitro inhibition of parasite invasion, IgG isolated from serum pools of AMA1-C1/Alhydrogel + CPG 7909 animals was more effective against both FVO and 3D7 parasites than an equal concentration of IgG from animals receiving vaccines adjuvanted with Alhydrogel alone. These promising preclinical results have recently led to the start of a Phase 1 trial in the US.
authors.affiliation: Malaria Vaccine Development Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5640 Fishers Lane, Rockville, MD 20852, USA. gmullen@niaid.nih.gov
authors.forename: Gregory E D
authors.initials: GE
authors.lastname: Mullen
authors.forename: Birgitte K
authors.initials: BK
authors.lastname: Giersing
authors.forename: Olubunmi
authors.initials: O
authors.lastname: Ajose-Popoola
authors.forename: Heather L
authors.initials: HL
authors.lastname: Davis
authors.forename: Cheryl
authors.initials: C
authors.lastname: Kothe
authors.forename: Hong
authors.initials: H
authors.lastname: Zhou
authors.forename: Joan
authors.initials: J
authors.lastname: Aebig
authors.forename: Gelu
authors.initials: G
authors.lastname: Dobrescu
authors.forename: Allan
authors.initials: A
authors.lastname: Saul
authors.forename: Carole A
authors.initials: CA
authors.lastname: Long
mesh_terms: D000536:Aluminum Hydroxide / Q000494:pharmacology*; D000818:Animals; D000913:Antibodies, Protozoan / Q000276:immunology*; D000917:Antibody Formation; D000918:Antibody Specificity; D006168:Guinea Pigs; D017780:Malaria Vaccines / Q000008:administration & dosage* / Q000276:immunology; D016778:Malaria, Falciparum / Q000276:immunology / Q000517:prevention & control*; D051379:Mice; D009838:Oligodeoxyribonucleotides / Q000378:metabolism; D010963:Plasmodium falciparum / Q000187:drug effects*; D051381:Rats
chemical_list: D000913:Antibodies, Protozoan; C408982:CPG-oligonucleotide; D017780:Malaria Vaccines; D009838:Oligodeoxyribonucleotides; D000536:Aluminum Hydroxide